By J. Duarte MDThe biotech sector has been a mixed affair of late, similar to the rest of the market.   The Biotech Index (BTK) continues to have a generally upward trend but is still well off its March highs.  It is still doing well for the year, having gained… Read More

Just as we believe innogration is the key to long term success for every tech company, so too do we feel it should be practiced by this publication so that our subscribers remain ahead of the curve. As you know, innogration consists of two critical components: innovation, which is achieved… Read More

I am adding Splunk to the Next Wave Portfolio because its solutions are increasingly being deployed across a variety of use cases— including traditional business intelligence (BI) functions—putting the company on a solid path to eventually reach $1 billion in annual revenue. Read More

These two biotech stocks offer a two-for-one proposition, which is a rare find in this sector. Read More

The utilities that best held their value during past periods of market turmoil could do so again. Read More

With so many data breaches, companies must have as much inside control as outside protection. Read More

The world economy can withstand the slowdown in Asia. Read More

Rising income from dividends should help U.S. investors endure the decline in the country’s exchange rate. Read More

The IMF revision doesn't change our U.S. investments or our Buy American thesis. Read More

A free-trade agreement would help diversify the country’s export markets. Read More